Literature DB >> 6197461

Cytotoxic T lymphocyte recognition of HLA-A/B antigens introduced into EL4 cells by cell-liposome fusion.

V H Engelhard, G A Powers, L C Moore, M J Holterman, M C Correa-Freire.   

Abstract

HLA-A2 and -B7 antigens were introduced into EL4 (H-2b) cells by cell-liposome fusion and were used as targets or stimulators for cytotoxic T lymphocytes (CTL) generated in C57B1/6 (H-2b) mice. It was found that such EL4-HLA cells were not recognized by CTL that had been raised against either a human cell line bearing these HLA antigens or the purified HLA-A2 and -B7 antigens reconstituted into liposomes. In addition, EL4-HLA cells were not capable of inducing CTL that could recognize a human cell line bearing HLA-A2 and -B7 antigens. Instead, EL4-HLA cells induced CTL that specifically lysed EL4-HLA cells and not human cells expressing HLA-A2 and -B7. CTL recognition required the presence of HLA antigens on the EL4 cell surface and was inhibited by antibodies against either H-2b or HLA-A/B. Monoclonal antibody binding studies showed that the expected polymorphic determinants of the HLA-A2 and -B7 antigens were still present on EL4-HLA cells. However, the specificity of CTL or their precursors that are capable of recognizing HLA-A2 or -B7 was altered after these antigens became associated with the EL4 surface. Possible explanations for these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  HLA antigens expressed on murine cells are preferentially recognized by murine cytotoxic T cells in the context of the H-2 major histocompatibility complex.

Authors:  M J Holterman; V H Engelhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 2.  Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.

Authors:  Arbel Artzy-Schnirman; Sivan Arber Raviv; Ofri Doppelt Flikshtain; Jeny Shklover; Netanel Korin; Adi Gross; Boaz Mizrahi; Avi Schroeder; Josué Sznitman
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 15.470

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.